Cellular resistance to anthracyclines is often associated with an unfavorable clinical outcome in a variety of cancers, including leukemia. Several mechanisms of anthracycline resistance may be involved such as an impaired transport of drugs across the plasma membrane, an increased drug efflux, an increased intracellular detoxification of drugs, a reduced availability of intracellular drug targets, or a reduced ability of cells to induce apoptosis. Here, we review the studies published about mechanisms which may explain resistance to anthracyclines in leukemic cells of pediatric patients.
Introduction
Anthracyclines are antibiotics that were also demonstrated to have anti-cancer activity 30 years ago. In 1966, Jacquillat and colleagues 1 reported for the first time that daunorubicin (DNR, also known as daunomycin or rubidomycin) had anti-leukemic activity in children with acute lymphoblastic leukemia (ALL). In subsequent years, many new analogues have been generated which mainly differ from DNR by changes in the aglycone part of the molecule (Figure 1 ), eg doxorubicin (DOX) differs from DNR by OH replacing H at the C14 position whereas idarubicin (IDA, also called 4-demethoxy daunorubicin) differs from DNR by the absence of the methoxyl group at the C4 position. Nowadays, anthracyclines are commonly used in the treatment of childhood and adult acute leukemia. During the past decades the prognosis of ALL and acute myeloid leukemia (AML) has considerably improved in children. However still 25% of ALL and 50% of AML children relapse, and once relapsed, the prognosis of these children is poor (5-year eventfree survival Ͻ35%). [2] [3] [4] The unfavorable prognosis associated with several cell biological features of leukemic cells may (partly) be explained by resistance to anthracyclines. Table 1 shows an overview of risk factors that are related to cellular anthracycline resistance in childhood acute leukemia.
The cytotoxicity of anthracyclines can be explained by several mechanisms of action including targets that are located inside the cell and at the cell surface. The binding of anthracyclines to DNA and their interaction with DNA helicases and DNA topoisomerases hampers the transcription, replication and repair of DNA. [8] [9] [10] [11] These processes are crucial for the maintenance of normal physiological functions within the cell and, therefore, interference with these processes is lethal to cells. Another toxic action of anthracyclines is the generation of free radicals that cause DNA damage and lipid peroxidation. 12 The selectivity of anthracyclines for negatively charged membranes and the peroxidation of cardiac lipids by free radicals may account for an important side-effect of anthracyclines, ie cardiotoxicity. 13, 14 Anthracyclines may also be cytotoxic by direct binding to the plasma membrane and/or direct induction of CD95 (also called APO-1 or Fas)-mediated programmed cell death. 15, 16 Many studies have been published on putative mechanisms of resistance to anthracyclines in leukemic cells. An overview of these mechanisms is shown in Figure 2 . The aim of the present review is to summarize the current knowledge about mechanisms of cellular anthracycline resistance in childhood acute leukemia. When relevant, data obtained from adult acute leukemia samples and leukemic cell lines will be discussed.
Mechanisms of cellular resistance to anthracyclines

Interaction of anthracyclines with the plasma membrane
Resistance to anthracyclines may occur at the cell surface. Cell line studies showed that DOX conjugated to beads or to transferrin killed leukemic cells without entering the cell. [17] [18] [19] Other studies reported that the composition of the lipid bilayer differed between anthracycline-resistant and parental leukemic cells. 20 , 21 Incorporation of polyunsaturated fatty acids in the lipid bilayer, which enhances the fluidity and per- Table 1 Risk factors related to anthracycline resistance in childhood acute leukemia.
Risk factor
In vitro response to anthracyclines Ref.
Sensitive Resistant
Type of leukemia ALL AML 5 Disease status initial relapse 6 Age 1.5-10 years Ͻ1.5 years 7 у10 years Immunophenotype common and preB ALL proB and T-ALL 7
Figure 2
Overview of possible mechanisms of cellular anthracycline resistance in acute leukemia. ER, endoplasmic reticulum; LRP, major vault protein/lung resistance protein; MRP, multidrug resistance-associated protein; P-gp, P-glycoprotein; topo II, DNA topoisomerase II. Diamonds indicate anthracycline molecules. meability of membranes, was shown to increase the uptake of and sensitivity to DOX in cell lines. 22, 23 However, several other studies did not demonstrate an altered lipid composition in anthracycline-resistant compared with sensitive cell lines. 24, 25 It is as yet unknown whether the lipid composition of plasma membranes is related to anthracycline resistance in leukemia patients.
Transport of anthracyclines across the plasma membrane
Anthracyclines most likely enter the cell by passive diffusion of the electrically neutral molecule. The lipophilic anthracyclines such as IDA accumulate much faster compared with relatively hydrophilic compounds such as DOX and DNR, but they may also efflux faster out of the cell unless the drug is protonated. [26] [27] [28] The therapeutic benefit of IDA compared with DNR is probably limited in childhood ALL because in vitro cross-resistance to DNR, DOX, IDA and other anthracyclines has been observed. 29 In addition, in randomized trials the clinical response using either IDA or DNR did not markedly differ in both children with ALL 30, 31 and AML. 32 In contrast, randomized trials in newly diagnosed adult AML patients showed that IDA was more effective than DNR. [33] [34] [35] However, the variation in dose equivalence used for IDA compared with DNR hampers the comparisons between studies, for example the ratio of DNR to IDA dose varied between four-and fivefold in the above-mentioned studies.
Inconsistent results have been reported about the relationship between the intracellular DNR content and the clinical response to chemotherapy (including an anthracycline) in adult AML. Some studies showed that the intracellular DNR content was lower in patients who failed to respond to chemotherapy compared with patients achieving a complete remission, 36, 37 whereas in other studies no difference was observed. 38, 39 We recently showed that the intracellular DNR content did not differ between initial and relapsed childhood ALL samples nor did the intracellular DNR content correlate with the cytotoxicity of DNR in these patients. 40 Remarkably, the leukemic cell size correlated with resistance to the anthracyclines DNR and IDA but not to other classes of drugs such as prednisolone, vincristine, l-asparaginase and etoposide (VP16) in childhood ALL. 40 Moreover, leukemic cells of relapsed patients were larger than cells of patients at initial diagnosis of ALL. 40, 41 The relationship between cell size and anthracycline resistance suggested that the cytotoxicity of DNR may depend on the intracellular DNR concentration rather than the intracellular DNR content. This suggestion was confirmed by the observation that the intracellular DNR concentration inversely correlated with in vitro DNR resistance in childhood ALL. 40 The intracellular DNR concentration was also lower in relapsed ALL compared with initial ALL samples, which may explain why relapse samples are more resistant to DNR than patients at initial diagnosis of ALL. 6, 40 The question remains which mechanism(s) contribute(s) to the lower intracellular DNR concentration in leukemic cells.
Drug resistance proteins
Permeability-glycoprotein:
The permeability-glycoprotein (P-gp), encoded by the multidrug resistance (MDR1) gene, is a transmembrane protein that belongs to the family of ATPbinding cassette (ABC) transporter proteins. Transfection of MDR1 cDNA into cell lines conferred resistance to different classes of drugs, including anthracyclines, vinca alkaloids and epipodophyllotoxins. 42 P-gp decreases the intracellular drug content by an active extrusion of the drug. The efflux of drugs can be (partly) inhibited by modulating agents such as verapamil, cyclosporin A and PSC 833. Table 2 summarizes the data reported on expression and activity of P-gp in childhood acute leukemia. Less than 30% of the samples taken at initial diagnosis of ALL and AML were P-gp positive. Some studies showed that the expression of Pgp was higher at relapse, ie especially at second or later relapse, compared with initial diagnosis of ALL 49, 55, 57 whereas the majority of studies did not demonstrate a relationship between P-gp expression and disease status in childhood acute leukemia. 5, [44] [45] [46] [47] [48] 51 P-gp expression did not differ or was even lower in childhood AML compared with ALL samples, although AML patients have a poorer prognosis and are in vitro more resistant to drugs (including anthracyclines) compared with ALL patients. 5, 62 The activity of P-gp in a pooled group of childhood ALL and AML samples, as detected by the reversing effect of verapamil on the efflux of the marker molecule rhodamine 123, was higher in relapse than in initial samples. 55, 59 However, in another study the effect of four different modulators on DNR accumulation and retention did not differ between initial and relapse childhood ALL samples despite the fact that the relapse cells accumulated and retained less DNR and were in vitro more resistant to DNR. 40, 61 In addition, the effect of modulators on the in vitro cytotoxicity of DNR was only small and not related to P-gp expression in ALL children. 48, 61 Besides the absence of a clear relationship between P-gp and anthracycline resistance, P-gp expression at initial diagnosis was not an independent prognostic factor in childhood ALL and AML. 51, 53, 54, 56 One exception is a study by Goasguen et al 50 who observed a trend for the correlation between P-gp positivity at initial diagnosis and a lower probability of event-free survival in childhood ALL. However, only 36 children were included in this retrospective study. In contrast to childhood acute leukemia, the contribution of P-gp to treatment outcome in adult AML may be more evident, as has recently been reviewed by Marie et al. 63 In general, the studies published so far do not suggest that P-gp contributes to anthracycline resistance and treatment failures in childhood acute leukemia. However, these studies do not exclude the possibility that P-gp contributes to drug resistance in specific subsets of patients, such as in patients with multiple relapsed ALL 49, 57 or t(8;21) AML. 60 Although it is not our purpose to review technical aspects, we feel it is appropriate to mention several pitfalls in the study of P-gp and other drug resistance proteins in clinical samples: (1) the comparison between studies is hampered by the different methods that were used, ie immunocytochemistry, flow cytometry, reverse transcriptase polymerase chain reaction (RT-PCR), slot blot and the modulation of drug uptake and/or efflux: this also means that P-gp was studied at different levels of expression, ie mRNA or protein; (2) measurements were often not well-standardized; (3) false positive results may have been obtained due to contaminating non-leukemic cells such as normal bone marrow and peripheral blood cells that also express P-gp; 64, 65 and (4) data may have been confounded by the pooled analysis of different clinical risk groups.
A well-described pitfall in RT-PCR studies is the variation in mRNA levels of the internal control within and between samples (eg ␤-actin) and/or the presence of genomic DNA. This hampers the comparison of mRNA levels between samples. 66, 67 In flow cytometry and especially immunocytochemistry variations in measurements are caused by fluctuations in the efficacy of staining procedures due to differences in fixation methods and storage origin of samples (fresh or cryopreserved). 68 The activity studies of P-gp are also subjected to variation. Advantages of studying the reversing effect of modulators are: (1) leukemic cell size is not important because the reversing effect is expressed as the ratio between the intracellular drug content with and without modulator and (2) standardization of drug content measurements is less important because ratios are calculated. Disadvantages are: (1) only the relative increase in drug content is determined whereas the actual intracellular drug content or concentration may yield more relevant or additional information about drug resistance and (2) the contribution of other (unknown) factors on the intracellular drug concentration are disregarded because mainly the contribution of P-gp is studied.
In international working groups the lack of consensus in Pgp detection has been extensively analyzed and recommendations have been given for P-gp detection in tumor samples. 69, 70 The study groups concluded that more than one method should be used to demonstrate P-gp positivity, eg analysis of both P-gp expression and activity.
Multidrug resistance-associated protein:
Another ABC transporter protein that may be related to anthracycline resistance is the multidrug resistance-associated protein (MRP). Transfection with MRP cDNA made cells resistant to a variety of drugs including anthracyclines, vinca alkaloids and epipodophyllotoxins which resembles the drug cross-resistance pattern of P-gp overexpressing cells. 71 Similar to P-gp, MRP may enhance the efflux of drugs out of the cell, although the substrate affinity/specificity may be different. 72, 73 Besides a function at the plasma membrane, the co-localization of MRP with the endoplasmic reticulum, Golgi complex and vesicles suggests that MRP may also be involved in the intracellular distribution and/or sequestration of drugs. 74, 75 Only a few studies have been reported about the clinical relevance of MRP in acute leukemia. In adult AML, no or only Table 2 Overview of results reported on expression and activity of P-glycoprotein in childhood ALL and AML 76, 79 The basal expression was also observed in a variety of other tumors and corresponding normal tissue. 80 MRP expression was inversely related to the accumulated DNR content, however, this may also be due to co-expression of P-gp in adult AML samples. 81, 82 Zhou et al 78 reported a lower complete remission rate in MRP positive compared with MRP negative adult AML patients but other studies did not demonstrate this difference. 76, 77, 83 In childhood ALL, MRP expression did not differ between initial and first relapse samples. The expression of mRNA but not of the protein was higher in multiple relapse ALL samples. 5, 57 In a paired analysis of initial and relapse samples collected from eight ALL patients both increased and decreased expression of MRP at relapse was observed. 5 No relationship was found between MRP expression and in vitro DNR resistance or between MRP expression and the accumulated DNR concentration in childhood ALL. 5, 40 Expression of MRP in AML and ALL samples was comparable despite the relative resistance to anthracyclines in AML patients. 5 In summary, although cell line studies indicated a clear relationship between MRP expression and anthracycline resistance, the contribution of MRP to DNR resistance in childhood acute leukemia is presumably of minor importance.
Major vault protein/lung resistance protein:
A putative drug resistance protein that does not belong to the family of ABC transporter proteins is the lung resistance protein (LRP). This protein was initially identified in anthracycline-resistant non-small cell lung cancer cells which did not express P-gp. 84 Cloning of the gene revealed that LRP is the human major vault protein, which contributes to more than 70% of the mass of vault particles. 85 Vaults are barrel-like structures which consist of four different vault proteins and a species of small RNA called vault RNA. 86 The physiological function of vaults is as yet unknown, but the co-localization of vaults with the nuclear membrane and vesicles has lead to the hypothesis that vaults are involved in nuclear cytoplasmic and/or vesicular transport. 84, 87, 88 Theoretically, LRP/vaults may contribute to anthracycline resistance by decreasing the amount of drug in the nucleus, by sequestering drugs in vesicles, by drug binding or by transporting drugs out of the cell.
Recently, the number of vaults was shown to be increased in cell lines selected for DOX resistance. 89 In cell lines that were not previously exposed to drugs LRP expression correlated with resistance to DOX, vincristine and platinum compounds. 90 Transfection of cells with LRP cDNA did not confer resistance to drugs. 85 However, besides LRP also three other proteins and vault RNA are needed to assemble a functional vault particle.
In adult AML, LRP expression was found in 35-50% of patients. [91] [92] [93] [94] Two studies showed a lower complete remission rate and probability of survival in LRP-positive patients. 91, 92 However, preliminary data reported by two other groups did not show a relationship between LRP expression and clinical outcome or in vitro resistance to anthracyclines in adult AML. 94, 95 In childhood ALL, expression of LRP did not or only weakly differ between initial and unrelated relapse samples nor did the expression in paired initial and relapse samples differ. 5, 96 However, multiple relapse ALL samples expressed more LRP compared with initial and first relapse ALL samples. 5 The expression of LRP in children with AML at initial diagnosis was higher than in ALL at initial diagnosis. 5 The expression of LRP weakly correlated with in vitro DNR resistance as well as with the accumulated (but not the retained) DNR concentration in childhood ALL. 5, 49 Also in adult ALL and AML an association has been observed between LRP expression and DNR accumulation (but not rhodamine 123 retention).
The increased expression of LRP in unfavorable risk groups and the relationship with accumulation of and resistance to DNR implies that LRP somehow is linked to cellular anthracycline resistance in childhood ALL, either as a epiphenomenon associated with resistance or as part of a mechanism causing resistance. Further knowledge about the physiological function of LRP/vaults is required to elucidate the way these molecules may contribute to anthracycline resistance in leukemic cells.
Other potential drug resistance proteins:
A potential drug resistance protein is the membrane protein P95 which was initially found to be overexpressed in DOX-resistant breast cancer cell lines. 98 Recently, the corresponding gene encoding the P95 protein has been identified as the nonspecific cross-reacting antigen (NCA-90).
99 P95 has been demonstrated in approximately 35% of adult AML samples. 100 The accumulation of DNR in P95-positive cells was lower than in P95-negative AML cells and this accumulation deficit could not be reversed by modulators such as cyclosporin A and verapamil. The importance of this protein for anthracycline resistance is presumably limited because the expression of P95 was not related to the degree of resistance to DNR in adult AML. 100 Moreover, a recent study showed that cells transfected with NCA-90 cDNA were not more resistant to DNR and did not accumulate less DNR compared with control cells. 99 In the past few years several new members of the ABC transporter family have been identified, such as the sister of P-gp (sP-gp), the transporter associated with antigen processing (TAP), the anthracycline resistance-associated protein (ARA) and five new homologues of MRP (MRP2 or cMOAT, MRP3, MRP4, MRP5, MRP6).
101-104
The sister of P-gp gene has been identified in the liver of pigs, but whether it is also expressed in human tissues is unknown. 101 TAP is a heterodimer that is composed of TAP1 and TAP2 proteins. The heterodimer mediates the peptide translocation from the cytosol into the endoplasmic reticulum. 102 These peptides are then coupled to class I molecules of the major histocompatibility complex and the assembled complex is translocated to the plasma membrane for presentation to cytotoxic T lymphocytes. Besides its role in class I restricted antigen presentation, TAP has recently been associated with drug resistance. Transfection of TAP1 and TAP2 genes into TAPdeficient lymphoblastic cells resulted in resistance to MDRrelated drugs including DOX. 105 TAP might contribute to resistance by facilitating the sequestration of anthracyclines in the endoplasmic reticulum but this hypothesis awaits further investigation.
The ARA gene encodes a 49.5 kDa protein which resembles the C-terminal half of the MRP molecule. 103 ARA mRNA levels were higher in an anthracycline-resistant subline compared with the parental lymphoblastic leukemia cell line. 103 It is not yet known whether the ARA protein is identical to the 45 kDa protein that was recognized by a MRP polyclonal antibody. 106 Kool and colleagues recently described five new homologues of MRP (now called MRP1), the cDNA of four of these homologues has been cloned. 104 In a first attempt to determine the relationship between MRP2, MRP3, MRP4, MRP5 and drug resistance, the levels of MRP2-5 mRNA were analyzed in a panel of DOX and cisplatin selected cell lines. Only the MRP2 mRNA level was related to cisplatin resistance whereas no relationship with DOX resistance was found. The 3Ј end of the MRP6 gene corresponds with the 3Ј end of the ARA gene. Together with the fact that the ARA protein resembles the C-terminal half of the MRP molecule these data support the hypothesis that ARA is a splice variant of MRP6. 103, 104 Whether the similarity between MRP6 and ARA genes also means that MRP6 is related to anthracycline resistance needs to be further investigated.
The physiological function of the above-mentioned proteins, except TAP, is largely unknown and, as a consequence, also the way they may contribute to the response to anthracyclines and other drugs is unknown. Further studies are needed to address these issues and to reveal the clinical importance of these proteins in acute leukemia.
Detoxification of anthracyclines
Other factors that may contribute to anthracycline resistance are the metabolism and inactivation of these drugs by different enzymes.
Metabolism of anthracyclines:
Anthracyclines can be reduced at their ketone group into C13-hydroxy alcohols, a process which is being catalyzed by aldehyde and carbonyl reductases. 107 Besides in the liver, reductases are also present in normal peripheral blood lymphocytes and bone marrow hematopoietic cells. 108 In vitro exposure of leukemic cells to different C13-hydroxy metabolites showed that these compounds were less cytotoxic than the parent drug. 109, 110 One exception is the C13-hydroxy metabolite of IDA, ie idarubicinol, which is equitoxic with IDA. 109 The other C13-hydroxy metabolites are less lipophilic and thus the uptake into the cell will be less efficient compared with the parent drug. More convincing evidence for a decreased cytotoxicity of the C13-hydroxy metabolites has been shown by transfection of carbonyl reductase into reductase-deficient myeloid leukemic cells. 111 Exposure of transfected cells to DNR resulted in high levels of the C13-hydroxy metabolite daunorubicinol and reduced cytotoxicity of DNR compared with control cells.
In adult AML, Huffman and Bachur 112 initially reported a higher reductase activity in leukemic cells of patients responding to DNR compared with non-responders to DNR. In contrast to the cell line studies, this suggests that daunorubicinol may be more cytotoxic than the parent drug. However, subsequent studies did not demonstrate marked differences in the percentage of cellular daunorubicinol between responders and non-responders to induction chemotherapy in adult acute leukemia. 113, 114 The relevance of anthracycline metabolism for drug resistance therefore remains questionable.
Glutathione S-transferases and reduced glutathione:
A second pathway of drug detoxification involves glutathione Stransferases (GSTs) and reduced glutathione (GSH). In human cells five classes of GSTs have been detected. To date three classes, ie ␣, and , have been associated with resistance to alkylating agents, anthracyclines and glucocorticoids. GSTs may detoxify drugs or other xenobiotics in three ways: (1) by catalyzing the conjugation of GSH to drugs which increases the water solubility and excretion of drugs, (2) by eliminating toxic free radicals generated by drugs and (3) by sequestering drugs for example by direct binding of the drug. [115] [116] [117] Resistance to anthracyclines may be related to the free radical protection by GSTs, 118 although controversial data have been reported about the importance of free radicals in anthracycline cytotoxicity. 119 GSTs may also bind anthracyclines which may reduce the bioavailability of these drugs in the cell. The GST-mediated conjugation of GSH to anthracyclines is less likely to occur due to the chemical structure of these drugs. 118 In clinical studies, most attention has been paid to the expression of GST. The reason for this may be that elevated GST levels correlated with drug resistance (among others the anthracyclines) and P-gp expression in some cell lines. 120, 121 GST expression was higher in adult AML and childhood ALL compared with normal bone marrow cells and peripheral blood lymphocytes. [122] [123] [124] The contribution of GST to clinical treatment failures is unclear because the expression did not differ between initial and relapse ALL and AML cases nor was GST an independent prognostic factor in childhood ALL and adult AML. 53, 122, [125] [126] [127] We recently observed that in addition to GST, expression of GST␣, and to a lesser extent also GST, was increased in childhood ALL cells compared with normal peripheral blood lymphocytes. Similar to GST, initial and relapse samples did not differ in the expression of these two proteins (Den Boer et al, submitted). Hall and colleagues 128 showed that elevated expression of GST at initial diagnosis, but not GST␣ and GST, was related to a poorer long-term prognosis. This relationship is presumably not caused by a poorer clinical response to anthracyclines because a correlation between GST (as well as GST␣ and GST) and in vitro DNR resistance was not found (Den Boer et al, submitted). AML and ALL patients at initial diagnosis demonstrated different patterns of expression of GSTs; expression of GST␣ was lower whereas GST and GST were more highly expressed in AML cells compared with ALL cells (Den Boer et al, submitted) . It is unknown whether this different expression pattern correlates with in vitro resistance of AML cells to drugs (including anthracyclines) and with the poorer prognosis of these patients compared with ALL patients.
The GSH/GST detoxifying pathway is a complex system with probably many co-factors still undetermined. Besides the expression and activity of GSTs, the quantity of GSH has been related to anthracycline resistance in cell lines. 129, 130 Because anthracyclines are unlikely to form conjugates with GSH, GSH should contribute to resistance in another way. Depletion of GSH resulted in a reversal of DNR accumulation deficits in MRP but not in P-gp expressing cell lines. 131 It is as yet unknown how a lack of GSH interferes with the transport of anthracyclines out of the cell. An explanation might be that GSH modifies the topology or active sites of MRP or that GSH modifies other unknown factors that are associated with drug transport. In childhood ALL, the lower intracellular DNR concentration in resistant cells was not related to MRP expression. 5, 40 In a small group of patients, high GSH levels were related to in vitro DNR resistance in childhood ALL. 132 This latter observation supports a possible role for GSH in anthracycline resistance, but whether this is related to transport of anthracyclines out of leukemic cells needs further study.
Intracellular targets of anthracyclines DNA topoisomerases:
The cytotoxicity of drugs also depends on the availability of and accessibility to intracellular target(s). The main target enzymes of anthracyclines are the type II DNA topoisomerases. Topoisomerases II generate transient double-stranded breaks in the DNA by so-called cleavable complex formation with the DNA. These DNA breaks are important in the transcription, replication and recombination of DNA. Topoisomerases are also involved in the segregation of chromosomes during cell division. 133 Two isoenzymes of topoisomerase II exist, ie II␣ and II␤ isoforms. The isoenzymes have been localized in different parts of the nucleus: topoisomerase II␤ expression is restricted to the nucleoli whereas topoisomerase II␣ is expressed in the remaining part of the nucleus in ALL cells. 134 The expression level of topoisomerase II␣ but not of II␤ is related to the cell cycle; ie the mRNA level is higher in S/G 2 M cells and expression is related to cyclin A and Ki-67 expression. 57, [134] [135] [136] The cytotoxic effect of anthracyclines may depend on the number of cleavable complexes that can be stabilized by these drugs and the inability of the cell to repair the DNA lesions. Resistance to anthracyclines has been associated with decreased expression and activity of the topoisomerase II␣ in cell lines. 137, 138 In acute leukemia, the role of this isoenzyme in drug resistance is less obvious; topoisomerase II␣ mRNA levels did not differ between initial and relapse patients, neither in childhood ALL nor in adult AML. 49, 58, 134 One exception was a study by Beck et al 57 who demonstrated significantly lower topoisomerase II␣ mRNA levels in first and multiple relapse cells compared with initial ALL cells (mainly childhood ALL). In both childhood ALL and adult AML, topoisomerase II␣ mRNA levels were not related to the clinical response to combination chemotherapy (including an anthracycline). 54, 139, 140 Moreover, both expression and activity of topoisomerase II␣ did not correlate with the cytotoxicity of anthracyclines in leukemic cells. 134, 140, 141 Therefore, topoisomerase II␣ may be an indicator of the proliferative status of cells without a direct relationship with anthracycline resistance in acute leukemia.
In contrast to topoisomerase II␣, the activity of topoisomerase II␤ was higher in anthracycline-resistant compared with sensitive AML cells. 141 In a paired analysis of 17 adult AML patients, the II␣/II␤ activity ratio was lower at relapse than at initial diagnosis. 141 An explanation might be that the anthracycline cytotoxicity can be circumvented by a high topoisomerase II␤ activity irrespective of the topoisomerase II␣ activity in leukemic cells.
Telomerases:
The stabilization of topoisomerase II cleavable complexes by anthracyclines is a first step in the suicide of cells. However, in contrast to cell line studies, the role of topoisomerase II in leukemic cell killing by anthracyclines is probably limited. Several other proteins have been associated with DNA metabolism, such as DNA helicases (which separates DNA strands) and telomerases. 9, 142 Telomerases are ribonucleoproteins that add specific DNA sequences (TTAGGG) to the telomeres of chromosomes. In this way telomerases compensate for the telomeric losses which occur during the replication of DNA and contribute to the ability of cells to proliferate. Elevated expression and activity of telomerases have been observed in acute leukemia compared with normal hematopoietic cells. [143] [144] [145] The activity of telomerases was associated with poor prognostic features in adult AML, such as high white blood cell count, unfavorable cytogenetic abnormalities and extramedullary presence of leukemic cells. 145, 146 The telomerase activity was higher at relapse compared with initial diagnosis in six out of 13 adult AML patients. 145 In five children with ALL, the telomeric length was shorter in the leukemic cells before treatment compared with non-leukemic cells examined when these patients were in complete remission. 147 However, evidence is lacking about a direct role of telomerases in anthracycline resistance.
Induction of programmed cell death CD95-mediated programmed cell death:
The ability of leukemic cells to survive treatment may also depend on the inability of cells to respond to cell death inducing signals. In the past years it became evident that anthracyclines, besides interacting with topoisomerase II, can also directly induce programmed cell death (apoptosis).
In hematopoietic cells, apoptosis can be triggered by binding of CD95-ligand to the cell surface CD95-receptor (also called Fas or APO-1). 148, 149 The CD95 receptor/ligand interaction is important for the regulation of the number of lymphocytes in normal blood. Death of these cells can be the result of both autocrine and paracrine induction of the CD95-mediated apoptotic pathway. [150] [151] [152] [153] Children with mutations in the CD95-receptor suffer from uncontrolled proliferation of lymphocytes due to dysfunctioning of the CD95-mediated apoptotic pathway (Canale-Smith syndrome). 154, 155 The expression of CD95-ligand and CD95-receptor was lower in anthracycline-resistant T-ALL cell lines compared with parental cells. 16, 156 The degree of anthracycline resistance and inability to trigger CD95-mediated apoptosis were correlated in these cells. 16, 156 Approximately 70% of childhood T-ALL samples expressed the CD95-receptor and the expression was higher in T-ALL compared with precursor Blineage ALL. 157, 158 However, in the majority of samples binding of CD95-ligand-mimicking antibodies to the CD95-receptor did not induce apoptosis (Ͻ20% apoptotic cells). 157, 158 These studies suggest that constitutive expression of CD95-receptor may be insufficient to mediate apoptosis in acute leukemia. De novo synthesis of CD95-ligand in cytotoxic T lymphocytes was required before CD95-mediated apoptosis of effector cells could be triggered by these cells. 150, 159 Newly synthesized CD95-receptor was also required to trigger CD95-mediated apoptosis in CD34-positive hematopoietic cells. 148 Not all cells responded to CD95-directed apoptotic stimuli; in cells of myeloid origin, ie adult AML and myeloid cell lines, CD95-mediated apoptosis could not be induced despite de novo synthesis of CD95-receptors. 160, 161 In contrast to myeloid cell lines, lymphoblastic leukemia cell lines were more sensitive to CD95-mediated apoptosis. 161 Possible explanations are that the de novo synthesized CD95-receptors are not functional in myeloid cells, for example due to mutations, or that the downstream signaling pathway is blocked in these cells.
Interestingly, anthracyclines were able to induce de novo synthesis of CD95-ligand and CD95-receptor in anthracycline-sensitive but not in -resistant neuroblastoma and T-ALL cell lines. 16, 162 Blocking of the CD95-receptor by inhibitory antibodies, which prevents the oligomerization of the receptor, also reduced the degree of anthracycline-induced apoptosis in these cells. 16, 162 However, other studies suggested that anthracycline-induced apoptosis occurred independently of CD95 in T-ALL cell lines (despite increased CD95-ligand expression). 163, 164 The CD95-dependent and CD95-independent pathways of apoptosis may collaborate because exposure to anthracyclines activated the same family of downstream effector molecules, ie the caspase family. 163, 165 The fact that anthracyclines can be cytotoxic without entering the cell has already been reported in 1982. 17, 18 It is tempting to think that these observations may be related to the induction of CD95-mediated apoptosis reported 15 years later!
Cell death regulatory proteins:
In each cell regulatory proteins are present which promote cell death, such as p53, bclxs and bax and proteins that inhibit cell death, such as mdm-2, bcl-2, bcl-xl and bad. 166 The balance between these proteins may be important for the decision of the cell to continue with the pathway of programmed cell death.
Mutations in the tumor suppressor gene p53 are infrequently detected at initial diagnosis of childhood ALL, ie Ͻ3% of the cases, whereas these mutations are more frequently found in adult AML, ie 15% of the cases. 167, 168 Mutations in the p53 gene are associated with a poor prognosis in both children and adults. [167] [168] [169] The stimulation of apoptosis by p53, eg after drug-induced DNA damage, 170 can be inhibited by mdm-2 which degrades the p53 protein. 171 Treatment failures in children with ALL were related to overexpression of mdm-2 protein at initial diagnosis. 172 Elevated levels of mdm-2 mRNA have been found in adult AML compared with normal bone marrow cells. 173 So far, anthracyclines have not been reported to interact directly with the p53/mdm-2 regulatory pathway in acute leukemia.
Expression of bcl-2, an inhibitor of apoptosis, was higher in children and adults with ALL or AML compared with normal hematopoietic cells. [174] [175] [176] Several studies reported a relationship between bcl-2 expression and poor clinical outcome or poor risk features in ALL and AML patients 122, 177, 178 whereas other studies did not observe this relationship. 174, 179, 180 The inconsistent results may be explained by the fact that not only bcl-2 but rather the balance between bcl-2 and other cell death regulatory proteins may be important in the control of apoptosis. Oltvai et al 181 showed that bcl-2 and bax form both homo-and heterodimers. The balance between these homoand heterodimers may be important for the decision of the cell to trigger the apoptotic pathway. 181 In adult AML, a high bcl-2/bax ratio was associated with a lower remission rate. 176 No relationship was found between the bcl-2/bax ratio and poor prognostic factors in children with ALL. 182 However, apoptotic stimuli may alter the bcl-2/bax ratio as was recently shown by Findley et al; 183 induction of DNA-damage by ␥-irradiation downregulated bcl-2 and upregulated bax expression in cell lines of childhood ALL.
Bcl-2 expression did not correlate with resistance to anthracyclines in childhood ALL. 174 It is unknown yet whether the bcl-2/bax ratio and regulation of the activity of bcl-2, bax and other cell death regulatory proteins, for example, by (de)phosphorylation, determine the cytotoxic effect of anthracyclines in acute leukemia. The ability of anthracyclines to induce CD95-mediated apoptosis and the downstream control over the apoptotic signal by cell death regulatory proteins offers new insights in the cytotoxic action of these drugs.
Concluding remarks
Multiple mechanisms of resistance to anthracyclines have been described in cell lines. These cell lines were often drugselected or transfected with the cDNA encoding the drug resistance protein in question. Strong correlations such as those reported in cell lines are seldom observed in clinical specimens. The heterogeneity between patients and among cell populations and the fact that resistance is a multifactorial phenomenon results, at most, in weak correlations. The large variation between patients may be diminished by analyzing data within specific subsets of patients. In our opinion, one should be careful with interpreting data of studies that use a mixture of different subtypes of leukemia, for example, pooled leukemic samples from children and adults or from ALL and AML patients. From the studies reviewed it may be clear that no single mechanism can explain anthracycline resistance in acute leukemia. P-gp, MRP and topoisomerase II␣ expression and activity are unlikely to play a major role in resistance to anthracyclines in childhood leukemia. The prognostic value of LRP in adult AML as well as the relationship between LRP expression, the intracellular accumulated anthracycline concentration and anthracycline resistance in children with ALL warrants further study of the physiological function of this protein. The contribution of the GSH/GST detoxification pathway to anthracycline resistance needs more attention, especially since preliminary results indicated a relationship between GSH levels and DNR resistance in childhood ALL. New developments in the search for anthracycline resistance mechanisms may be related to DNA replication (telomerases) and apoptosis (CD95-mediated). The next years will teach us whether these topics will help us to unravel the mechanisms of action and resistance to anthracyclines which are clinically relevant in childhood acute leukemia.
